Language: BG BG
← Back to results
Recruiting Not applicable NCT06088212

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

No applicable phase (e.g. observational)
Conditions: Heart Failure Cognitive Impairment Dementia Left Ventricular Dysfunction Cognitive Change Cognitive Decline

Sponsor: Baker Heart and Diabetes Institute

trial.available_in: БГ
Overview
This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.
Who can participate
Inclusion Criteria: 1. Hospitalised with HF as primary or secondary diagnosis. 2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge. Exclusion Criteria: 1. Unable to provide written consent; requiring palliative care; or participating in another RCT 2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded. 3. Terminal illness (eg. cancer) that may influence 12-month prognosis.
Locations 1
Australia (1)
Menzies Institute for Medical Research
Hobart , Tasmania
Technical details
Status
Recruiting
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
01.07.2024
Completion date
01.07.2026
Registry ID
NCT06088212
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.